hemCheck approved for trading on Nasdaq First North - Regulatory

13.3.2017 17:26 | NASDAQ OMX


hemCheck approved for trading on Nasdaq First North - Regulatory

This Press Release should not be released or distributed, directly or indirectly, within USA, Canada, Japan, Australia, Hong Kong, Switzerland, Singapore, South Africa, New Zealand or any other jurisdictions where distribution would be subject to legal restrictions.

Nasdaq First North has approved hemCheck Sweden AB's (publ) ('hemCheck' or the 'Company') application for listing of the Company's shares, and subscription option rights of series TO 1, for admission for trading on Nasdaq First North. The first trading day will be 15 March 2017. The ticker symbol for the Company's shares on First North is HEMC, the ticker symbol for the subscription option rights is HEMC TO 1.

hemCheck develops and commercializes a unique product concept (Helge(TM) and READY(TM)) that detects hemolysis in blood samples at the point of care. Nasdaq Stockholm AB has approved hemCheck's application for the Company's shares and subscription option rights (series TO 1) to begin trading on Nasdaq First North. The first day of trading will be March 15, 2017.

hemCheck CEO Annelie Brolinson:
"We're delighted interest in our share issue has been so great. We look forward to begin trading on 15 March. The whole team at hemCheck will continue to keep working hard to meet all our shareholders' expectations. As previously announced we will now finalize our product concept, consisting of Helge(TM) and READY(TM), for CE marking. We can then go full speed ahead with the market launch of our concept, starting in Sweden."

In February hemCheck announced that the company had received over 1900 new shareholders through a new issue of units. Each unit consisted of one share and one subscription option rights of series TO 1. With subscription option rights issued free of charge the subscription price per unit amounted to SEK 6 per share. The issue volume of 28.2 million initially signed to approximately 59 MSEK, a subscription rate equivalent to approx. 209%. As the rights issue was oversubscribed, the Board decided to make full use of an over-allotted issue. The company thus initially raised approx. 30 MSEK prior to listing, and if all share issue costs and / or all outstanding subscription option rights will be used before Q1 2018, the Company will receive an additional 30 MSEK before issue costs.

The ticker symbol for the Company's shares on First North is HEMC, the ticker symbol for subscription option rights is HEMC TO 1.

Conditions for subscription option rights
Possession of a series TO 1 subscription option rights entitles the owner to subscribe for one of the new shares at a price of SEK 6 for a period from 29 January 2018, up to and including 9 February 2018.

Full details on how warrants will be used for subscription of shares in hemCheck will be made available on the Company's website,, and Aktieinvest's website from 29 January 2018. Full terms and conditions for the warrants of series TO 1 will be detailed in the section Full terms and conditions for the warrants of series TO 1 in the prospectus being prepared for the new share issue, which is available on the Company website.

Corpura AB is the financial advisor for the new share issue, and Fredersen Advokatbyrå AB is acting legal advisor. hemCheck's Certified Adviser on Nasdaq First North will be Corpura AB. Aktieinvest FK AB is acting as receiving agent in connection with the rights issue.

About hemCheck
hemCheck Sweden AB (publ) develops and commercializes a unique product concept (HELGE(TM) and READY(TM)) that detects hemolysis in blood samples at the point of care. Hemolysis, or the rupturing of red blood cells, is the most common reason for blood samples being unfit for analysis-which can lead to poorer healthcare, increased risk for patients and higher costs for clinics and society. By detecting hemolysis in blood tests directly, HELGE(TM) can contribute to improved care for patients throughout the world. hemCheck is headquartered in Karlstad, Sweden. hemCheck prepared a prospectus for the issue of new units before its resumption of trading on Nasdaq First North.

hemCheck Sweden AB (publ)
Annelie Brolinson, CEO
Tel: +46 70 288 0826
Universitetsgatan 2
651 88 Karlstad

Important information
The information in this press release may not be published, reproduced or distributed in or into the United States, Canada, Japan, Australia, Hong Kong, Switzerland, Singapore, South Africa or New Zealand or any other country or other jurisdiction where such action is not permitted, or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities laws.

No interim units or units have been registered and will not be registered under the United States Securities Act of 1933 (the 'Securities Act') and may not be offered, subscribed to, sold or transferred, directly or indirectly, within the United States, except with the written approval from hemCheck and pursuant to an applicable exemption from the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction of the United states.

This is information which hemCheck is required to disclose according to EU Market Abuse Regulation law. The information was provided by the above contact person's auspices, for publication on 13 March 2017, 1725.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hemcheck Sweden AB via Globenewswire




Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Forterra Announces Second Quarter 2017 Earnings Schedule27.7.2017 22:30Pressmeddelande

IRVING, Texas, July 27, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra") (Nasdaq:FRTA) plans to release second quarter 2017 financial results before the market open on Thursday, August 10, 2017.  A conference call to review financial results will also be held on Thursday, August 10, 2017 at 8:30 a.m. Eastern time (7:30 a.m. Central).  Hosting the call will be Jeff Bradley, Chief Executive Officer, and Matt Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q2 2017 Forterra, Inc. Earnings Call Date: Thursday, August 10, 2017 Time: 8:30 a.m. Eastern Time (7:30 a.m. Central) Webcast: Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Parti

TGS Q2 2017 webcast and teleconference27.7.2017 18:14Pressmeddelande

ASKER, Norway, July 27, 2017 (GLOBE NEWSWIRE) -- TGS will release its Q2 2017 results at approximately 07:00 CEST on 3 August 2017. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at the Hotel Continental, Stortingsgata 24/26 in Oslo, Norway. The presentation is open to the public and can be followed live on the internet at The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. CEO Kristian Johansen and CFO Sven Børre Larsen will host a conference call on 3 August 2017 at 15:00 CEST (09:00 EDT). Attendees may want to call 5-10 minutes before to ensure registration and access. Norwegian attendees are invited to call + 800 51084 or + 47 2100 2610 International attendees are invited to call 0800 358 6377 or + 44 (0)330 336 9105 US attendees are invited to call +1 866-

Vistajet Launches New Digital Platforms as Growth Accelerates in China27.7.2017 14:36Pressmeddelande

VistaJet grows team and launches Chinese website owing to passenger demand VistaJet VistaJet Challenger 850  VistaJet Ltd For the six months to 30th June 2017: Program Membership sales increase globally by a record 57% as customer retention hits 91% across all regions 12% year-on-year increase on passenger departures from China 100% customer renewal rate in Greater China in the first half of 2017 VistaJet Chinese website launched at HONG KONG, July 27, 2017 (GLOBE NEWSWIRE) -- VistaJet continues to build on its China growth and demonstrates a commitment to the region by expanding its team and launching

Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 201727.7.2017 14:30Pressmeddelande

Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of 2017 on Thursday, August 3, 2017.  The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.  The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 53086270.  A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at  The archived webcast will be available on the Company's website beginning approximately two hours after

Vertiv Sells ASCO® to Schneider Electric27.7.2017 14:22Pressmeddelande

Sale enables greater focus on core business COLUMBUS, Ohio, July 27, 2017 (GLOBE NEWSWIRE) -- Vertiv, formerly Emerson Network Power, today announced plans to sell its ASCO® business as it continues to sharpen its focus on the digital critical infrastructure space. The $1.25 billion sale to Schneider Electric allows Vertiv to apply additional resources toward business and technological advancements in its core data center, telecommunications and commercial and industrial markets. As Vertiv has repositioned itself after being sold to Platinum Equity in November 2016, it became clear that ASCO's strengths in the automatic transfer switch arena fell outside the new organization's more focused strategy, said Vertiv CEO Rob Johnson. "This sale is a significant step forward in our evolution as the premier provider of digital critical infrastructure solutions," Johnson said. "This is consistent with our strategy of focus

TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan27.7.2017 13:00Pressmeddelande

-   Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia -   TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties WALTHAM, Mass. and OSAKA, Japan, July 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor. This agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum